What is dementia? (Dementia: what next? series)

Dementia Surge in the UK

The UK has entered a new phase in its dementia challenge. In 2025, the number of people living with the condition exceeded one million for the first time, up from 982,000 in 2024, with projections showing 1.4 million by 2040. This rise stems primarily from an ageing population and longer lifespans, making dementia the country's leading cause of death.

The financial implications are stark. Dementia already costs the UK economy £42 billion annually in healthcare, social care, and lost productivity, a figure expected to climb to £90 billion by 2040. Much of this burden falls outside the NHS, on families providing unpaid care and on individuals funding private support, exacerbating inequalities in access to quality care.

Policy responses have intensified. In late 2025, the government launched the Dementia Patient Flow R&I Challenge with £5 million in initial funding to accelerate diagnosis timelines, aiming for over 92% of patients diagnosed within 18 weeks by 2029 through tools like blood-based biomarkers and digital assessments. This builds on the 10-Year Health Plan's emphasis on prevention, early intervention, and research integration via initiatives like the Dame Barbara Windsor Dementia Goals Programme.

Yet significant hurdles remain. NICE's 2025 guidance rejected amyloid-targeting drugs such as lecanemab and donanemab for NHS use, citing insufficient benefits relative to high costs, leaving patients without access to the first disease-modifying treatments available elsewhere. This decision underscores a core tension: scientific progress in slowing progression clashes with fiscal constraints in a cash-strapped health service.

Broader angles include the push for risk reduction through addressing hearing loss, hypertension, and social isolation—factors with strong evidence—but implementation lags due to uneven public health infrastructure. Informal carers, often shouldering decades of responsibility, face burnout and financial strain without adequate support, while regional disparities in diagnosis rates persist despite national ambitions.